AxoGen Q3 2026 Earnings Date & Estimates

AxoGen (NASDAQ:AXGN) is a medical technology company focused on repairing and regenerating damaged peripheral nerves. The company develops and commercializes products for use by surgeons treating traumatic nerve injuries and other conditions in which nerve function has been compromised.

AxoGen’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft designed to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body. Its offerings also include Axoguard Nerve Connector and Axoguard Nerve Protector products, which are designed to support nerve repair and protect nerves during healing, as well as other products for peripheral nerve reconstruction.

Founded in 2002, AxoGen is headquartered in Alachua, Florida. The company markets its products primarily to hospitals and specialty surgeons in the United States and also serves selected international markets through direct sales and distribution relationships. Its products are used across areas including upper- and lower-extremity reconstruction, plastic and reconstructive surgery, orthopedic surgery, and other procedures involving peripheral nerve repair.